Clinical Trials

Asian, American Indian, Alaska Native, Latino and Hispanic patients are underrepresented in U.S. clinical trials for new drugs and biologics, compared with national census figures, according to a research letter published in JAMA.

Racial and ethnic minority populations remain underrepresented in many precision oncology trials relative to their cancer incidence in the U.S., according to study results published in JAMA Network Open.

A recent study showed that most cancer therapies tested in phase 3 trials lack survival benefits, prompting researchers to advocate for more stringent criteria to determine which therapies should advance to phase 3 development.

Although cancer clinical trial participation has increased among Black and Hispanic individuals, these populations — along with women and older adults — remained underrepresented, according to a study published in Cancer.

Cancer clinical trials remain underutilized by patients as a means of acquiring experimental drugs, tests and/or procedures that they otherwise might not be able to obtain.

More than 80% of therapies tested in phase 3 oncology trials did not demonstrate clinically meaningful benefit in extending survival, according to results of a study published in JNCCN — Journal of the National Comprehensive Cancer Network.

LAS VEGAS — Inflammatory bowel disease clinical trials underrepresent racial and ethnic minority groups, according to a presentation at the ACG Annual Scientific Meeting.

Black women have the highest mortality rate of all women with breast cancer in the U.S., with a significant number presenting at an earlier age of diagnosis and with more advanced-stage disease.

The sense of urgency surrounding the COVID-19 pandemic led to speedy development of several vaccines against the SARS-CoV-2 virus.

Racial disparities in cancer clinical trial enrollment have existed for decades, with Black, Hispanic and other underserved populations prevented from accessing the same cutting-edge treatments as their white counterparts.